Terapêutica Página 2

WHO - Therapeutics and COVID-19: living guideline

World Health OrganizationCurrent practice to treat COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized controlled trials (RCTs) of many different drugs are underway to inform practice. This version of the World Health...

NEJM - Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

The New England Journal of Medicine

Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).

NEJM - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

The New England Journal of MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal...

The Lancet - Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study

Little is known about the practice of ventilation management in patients with COVID-19. We aimed to describe the practice of ventilation management and to establish outcomes in invasively ventilated patients with COVID-19 in a single country...

BMJ - Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

British Medical JournalWith few treatment options available to manage coronavirus disease 2019 (covid-19), the disease presents a unique set of challenges for healthcare providers globally. In addition to using non-drug interventions, health...

NEJM - Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

The New England Journal of MedicineThe efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear.

JAMA - Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

JAMA NETWORK

What is the effect of tocilizumab, an anti–interleukin-6 receptor antibody, in patients with COVID-19 and moderate-to-severe pneumonia?

NEJM - Remdesivir for the Treatment of Covid-19 — Final Report

The New England Journal of MedicineAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.

The Lancet - Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study

The LancetHydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to examine whether patients with rheumatological conditions receiving...

JAMA - COVID-19 and the Path to Immunity

JAMA NETWORKThe emergence of adaptive immunity in response to the novel Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurs within the first 7 to 10 days of infection. Understanding the key features and...

The Lancet - Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomise

The LancetThe efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted...

JAMA - Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - A Meta-analysis

JAMA NETWORK

Is administration of systemic corticosteroids associated with reduced 28-day mortality in critically ill patients with coronavirus disease 2019 (COVID-19)?

JAMA - Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 - The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

JAMA NETWORKDoes intravenous hydrocortisone, administered either as a 7-day fixed-dose course or restricted to when shock is clinically evident, improve 21-day organ support–free days (a composite end point of in-hospital mortality and the...

JAMA - Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

JAMA NETWORKIn patients with coronavirus disease 2019 (COVID-19) and moderate or severe acute respiratory distress syndrome (ARDS), does intravenous dexamethasone plus standard care compared with standard care alone increase the number of days...

JAMA - Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

JAMA NETWORK

Does low-dose hydrocortisone decrease treatment failure in patients with COVID-19–related acute respiratory failure?

WHO - Therapeutics and COVID-19: living guideline

NEJM - Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

NEJM - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

The Lancet - Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study

BMJ - Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

NEJM - Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

JAMA - Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

NEJM - Remdesivir for the Treatment of Covid-19 — Final Report

The Lancet - Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study

JAMA - COVID-19 and the Path to Immunity

The Lancet - Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomise

JAMA - Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - A Meta-analysis

JAMA - Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 - The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

JAMA - Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

JAMA - Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

Categorias

Arquivo